Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995147 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
A Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT03995147 is a Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 51 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03995147, a Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG R-CHOP Protocol
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2027-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03995147
The ClinicalTrials.gov registry entry for NCT03995147 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03995147 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03995147 about?
NCT03995147 is a clinical study titled "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma". This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
What is the current status of trial NCT03995147?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2019-08-29. Estimated completion is 2027-02-20.
What conditions does trial NCT03995147 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B Cell Lymphoma, B-cell Lymphoma, Lymphoma, B-Cell, High Grade B-Cell Lymphoma.
What interventions are being tested in trial NCT03995147?
The interventions under investigation include: Pembrolizumab (DRUG), R-CHOP Protocol (DRUG).
Who is sponsoring clinical trial NCT03995147?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03995147 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.